Scoop: Adam Koppel's Bain team has another $1.9B to wager on life sci companies. And he likes their odds
Adam Koppel filed his first Form D for his life sciences group at Bain almost exactly 5 years ago. After jumping from a strategy post at Biogen, he had some clear ideas on exactly how he and his then-fledgling team at Bain Capital Life Sciences would invest a sizable amount of capital in the industry.
He didn’t know it at the time, but it was extraordinarily good timing. Perfect timing for an industry that has been making landmark advances at the center of the world stage.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.